Get started
Cybin Inc.Cybin Inc.Cybin Inc.

Cybin Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

CYBN trade ideas

A Bear market bounce or something more?CYBN weekly bear break had significant followthrough - does today's big bounce change anything? Well, no, not yet. But we have a setup to change the hourly trend back to bullish tomorrow or Monday, and then from there bulls want to see the bounce continue high enough where we can expect a higher low above the low of the bear break at 6.25. One day at a time, but out of all the charts I cover, this is the only one where the bears remain firmly in control and comfortable. I publish regular technical analysis of the psychedelic sector. Be sure to like and follow to not miss an important update!
AMEX:CYBN
by McGuireTO
CYBN bears starting to get followthrough on the bear breakCYBN weekly bear break from last week is starting to followthrough with four days in a row or larger than average volume on four red days. I've cut my loss on the break of the 7.11 level I've been talking about for two months now, and I'm not interested in taking another position unless we get daily oversold on this pullback. I publish regular technical analysis of the psychedelic sector. Be sure to like and follow to not miss an important update!
AMEX:CYBNShort
by McGuireTO
CYBN in sideways channel, bulls need to break above 8.01Nothing changes for me between 7.11 and 8.01. Break below and I will stop out of my swing and be very patient while I reassess, break above 8.01 and we look for a lower high below 9.83. Currently, 4hr EMA12 continues to be resistance on each little bounce attempt. If you are bullish here, you have decent entry opportunity to play off of 7.11 support with a stop loss below that - you'll certainly be in a much better position with your position than I am with mine on this stock!
AMEX:CYBN
by McGuireTO
The Convoluted Wellness Movement Say what you will about RFK Jr, but his ideas, if implemented even in some small ways, would have a drastic impact on the psychopharmaceutical industry. I'm a therapist myself, and I can't tell you how many teenagers are placed on SSRIs and ADHD medication without careful consideration for long term effects. Not that these medications are poisonous - they can be very helpful for many. I do think they are overprescribed, however, and can lead to lifelong dependency if not used carefully or with intent. While I don't think psychedelics would be great for teenagers and their developing brains (says the guy who took mushrooms for the first time at 17), I do think they are a powerful alternative, and do not require as much consistent dosing. The pharmaceutical industry will try to push microdosing, so as to make greater profits. Do I think psychedelics will be implemented as mental health treatment successfully on the first go-around? Not necessarily. Do I think that certain people with a family history of psychosis and mood disorders should avoid psychedelics? Probably. The companies at the forefront of this research could be in a decent position to spike in value. They may be eventually bought out by other entities, of course, or simply lose their speculative value. Maybe this is already happening. I'm wondering if CYBIN in particular, is forming a bottom here. It does look trapped in an endless wedge, with every pump getting aggressively sold. However, volume is steadily increasing week by week, which could indicate some hidden accumulation. MindMedicine may be positioned a little better, from a technical perspective. I've bought back into both MindMedicine and Cybin equally over the last day or two. Not a big position, but perhaps worth the gamble. Each could easily decline by 50% or more from here. MNDMD at least seems to have a healthier chart. The bigger concern is whether these companies' finances can withstand more time before regulatory clarity, as well as governmental stability as a whole. Things are looking very strange in the U.S. Either way, there is a movement (public or not) towards homeopathic medicine. I guess we'll see. This investment is entirely speculative, and seems just as likely to trend towards zero as it is to explode 10x in value. This is my personal opinion, and is meant for personal use only - not as financial advice. These stocks have relatively low volume and are prone to wild price swings.
AMEX:CYBNLong
by VictorCobra
1
CYBN youtubers pump over... Possible C or wave 3 is starting??The youtubers pump and dump is over IMO. They hype has worn off. I picked up some today and have a lower buy set in place. This is a hero or ZERO play for me. If it melts faces I'll take some profit before summer's end. Expecting a pump above .50 soonish and a retracement to under .40 and a flatline before the face melting happens. Merry Jane stocks had their pumps and GWAV paid me twice in the last two weeks time for the rotation IMO. Watch our on crypto I think we could see some alts crash 40%+ before summer and BTC to 25-38k. NOT FINANCIAL ADVICE!!!!
AMEX:CYBN
by Polarbearman
1
CYBIN - The Mushroom Long Term Play Amidst my re-evaluation of markets, divestment from crypto, and future planning, I'm slowly building a long term position in CYBIN. As a therapist who also happens to be a fan of psychedelics, this one fits me well. I think it can continue to flounder around, and perhaps test some even lower levels. Just looking for optimal entry points now, and managed to scoop some up the other day at $0.50. Over the next 10 years, I think the psychedelic mushroom industry will be an interesting place for growth. Screw tech. Mushrooms all the way! And not just the magic ones. I'll be on the lookout for other companies as well, and should probably devote some more time to research. I placed some theoretical targets for this, since the company is currently valued just under $100M. I think $3 Billion is fairly conservative, hence the $15 target. This is meant for speculation only, and not as financial advice. -Victor Cobra
AMEX:CYBNLong
by VictorCobra
4
CYBIN Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge. The considerably large acquisition puts Cybin in the limelight with credibility status in ongoing and future work - see Cybin’s recent acquisition announcement of DMT therapeutics developer Small Pharma DMTTF. Blake Mycoskie On His $100M Pledge To Psychedelics Research Following a sound pledge of $100 million for psychedelics research, billionaire Blake Mycoskie has updated on how his funding agenda -representing around 25% of his wealth- will unfold. Mycoskie says he is planning to “give $5 million a year for the rest of the time, until the $100 million runs out,” a yearly sum that “feels right, because the industry still feels nascent.” That could change in the presence of “a huge opportunity” or in the need of “a huge campaign push.” Although he understands other donors are waiting for further regulatory and scientific success, his personal standpoint is that those aren’t needed in view of solid works authored by Johns Hopkins and New York University, among others.
AMEX:CYBNLong
by CBKWahoo